Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07455942
Recruiting Observational

Towards an Understanding of Barriers and Delays in the Diagnosis of Anal Cancer

NCT07455942 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Intercommunal Creteil
Phase
Observational
Started
2026-06-23
Last updated
2026-09-01

Condition(s) studied

Squamous Cell Carcinoma of the Anal CanalHPV-induced Cancer

Investigational drug(s) / intervention(s)

self-administered questionnaire

self-administered questionnaire: Completion of a self-administered questionnaire by the patient to collect information about their care journey, any difficulties or hesitations, as well as their knowledge of the link between papillomavirus and cancer.

Study summary

This study examines care pathways in 300 patients with anal squamous cell carcinoma to identify barriers and delays in diagnosis, assess the impact of screening and access to care, and improve awareness, screening practices, and early diagnosis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Male or female ≥ 18 years 2. Histologically proven invasive or microinvasive squamous cell carcinoma of the anus 3. Having read and understood the information letter provided, either: i. After disclosure of the diagnosis, or ii. At the latest 6 months after initiation of treatment (surgical excision, radiotherapy, or chemoradiotherapy) 4. Affiliated with a social security system Exclusion Criteria: 1. Refusal to participate in the protocol 2. Other histological types: lymphoma, adenocarcinoma, neuroendocrine tumor, etc. 3. Time since treatment initiation greater than 6 months 4. Protected persons (pregnant women, breastfeeding women, individuals under guardianship or curators, minors, persons deprived of liberty, or persons unable to express informed consent).

Primary outcome measure(s)

Trial sites (32)

FacilityCityRegionStatus
CHU Angers Angers France Recruiting
CH Avignon Avignon France Not Yet Recruiting
Clinique Belharra Bayonne France Recruiting
CH Béthune Beuvry France Recruiting
CH du Haut Anjou Château-Gontier France Recruiting
Polyclinique du Parc Vivalto Cholet France Recruiting
Centre Hospitalier Intercommunal de Créteil Créteil France Recruiting
CH Annecy Genevois Épagny France Recruiting
Clinique du Palais Grasse France Recruiting
CH Vendée La Roche-sur-Yon France Recruiting
Cabinet de proctologie Le Bouscat France Recruiting
CH Lens Lens France Recruiting
Hôpital St Joseph St Luc Lyon France Recruiting
CHU Hôpital Nord - Marseille Marseille France Recruiting
CHU Montpellier Montpellier France Recruiting
Institut régional du Cancer de Montpellier (ICM) Montpellier France Recruiting
CHU Orléans Orléans France Recruiting
Hôpital Paris Saclay, GHNE Orsay France Recruiting
APHP_Hôpital Cochin-Port Royal Paris France Recruiting
Hôpital Saint Joseph Paris France Recruiting
Institut Mutualiste de Montsouris Paris France Recruiting
APHP_Hôpital Bichat Claude-Bernard Paris France Recruiting
APHP Hôpital Tenon Paris France Recruiting
Groupe Hospitalier Diaconesses Croix Saint-Simon Paris France Recruiting
Polyclinique Pau Pyrénées Pau France Recruiting
CHI Poissy-St Germain Poissy France Recruiting
Maison des consultations Quint-Fonsegrives France Recruiting
CHRU Ponchaillou de Rennes Rennes France Recruiting
Clinique Saint-Grégoire Saint-Grégoire France Recruiting
Hia Begin Saint-Mandé France Recruiting
Hôpital Bagatelle Talence France Recruiting
Centre Hospitalier Intercommunal de Villeneuve-Saint-Georges Villeneuve-Saint-Georges France Recruiting

More Centre Hospitalier Intercommunal Creteil trials in France

National Registry of Surgical Treatment and Percutaneous Cryoablation of Parietal Endometriosis Recruiting
Mapping and Characterization of Alveolar Cells During Smoking and Chronic Obstructive Disease Recruiting
Early Detection and Referral for Autism and Neurodevelopmental Disorders at the Maternal and Child Protection Services Recruiting
Pharmacokinetics-pharmacodynamics of Morphine With or Without Midazolam Administered by Continuous Infusion in Neonatal Intensive Care Recruiting
Intervention With General Practitioners to Improve Women's Participation in Cervical Cancer Screening Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07455942 on ClinicalTrials.gov ↗ ← All trials in France